"When you hear that you have cancer, it changes everything. It’s a diagnosis that can break your heart and turn your world upside down. At Providence, you’re never alone in this journey. The Providence St. Mary Regional Cancer Center in Walla Walla is exclusively devoted to comprehensive cancer care. Our doctors, nurses and other specialists will give you the best-possible support, therapies and care, whatever type or stage of cancer you have. Your care team includes specialty-trained doctors who cooperate to diagnose and treat common and rare cancers. Your cancer team will work closely with you and your family, too. We’ll plan effective treatments to help you feel better and realize the best-possible long-term outcomes."

During the past decade, Providence St. Mary Regional Cancer Center conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 9 clinical trials were completed, i.e. on average, 300% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 4 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Providence St. Mary Regional Cancer Center" #1 sponsor was "Celgene" with 5 trials, followed by "NSABP Foundation Inc" with 4 trials sponsored, "Hoffmann-La Roche" with 3 trials sponsored, "Eastern Cooperative Oncology Group" with 1 trials sponsored and "Novartis Pharmaceuticals" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Providence St. Mary Regional Cancer Center" #1 collaborator was "National Cancer Institute (NCI)" with 5 trials as a collaborator, "Genentech, Inc." with 2 trials as a collaborator, "American College of Surgeons" with 1 trials as a collaborator, "Breast International Group" with 1 trials as a collaborator and "Janssen, LP" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Providence St. Mary Regional Cancer Center" are "Breast Cancer" (6 trials), "B-Cell Chronic Lymphocytic Leukemia" (1 trials), "Chronic Lymphocytic Leukemia" (1 trials), "Chronic Lymphocytic Leukemia (CLL)" (1 trials) and "Colorectal Cancer" (1 trials). Many other conditions were trialed in "Providence St. Mary Regional Cancer Center" in a lesser frequency.

Most popular intervention types in "Providence St. Mary Regional Cancer Center" are "Drug" (10 trials), "Other" (2 trials), "Radiation" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Docetaxel" (2 trials), "Lenalidomide" (2 trials), "Placebo" (2 trials), "5-Fluorouracil" (1 trials) and "Atezolizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Providence St. Mary Regional Cancer Center" are 12 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Providence St. Mary Regional Cancer Center". undefined are not yet recruiting, 1 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Providence St. Mary Regional Cancer Center, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Providence St. Mary Regional Cancer Center, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".